OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022
Patrick R. Harrington, Jie Cong, Stephanie B. Troy, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1365-1370
Open Access | Times Cited: 13
Patrick R. Harrington, Jie Cong, Stephanie B. Troy, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1365-1370
Open Access | Times Cited: 13
Showing 13 citing articles:
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
Dallas J. Smith, Anastasia S. Lambrou, Pragna Patel
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1357-1364
Open Access | Times Cited: 21
Dallas J. Smith, Anastasia S. Lambrou, Pragna Patel
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1357-1364
Open Access | Times Cited: 21
Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review
A. Cha-Silva, M. Gavaghan, Tobias Bergroth, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 3, pp. e246-e257
Open Access | Times Cited: 5
A. Cha-Silva, M. Gavaghan, Tobias Bergroth, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 3, pp. e246-e257
Open Access | Times Cited: 5
Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant
Sophie Marbaix, Steven Simoens, Philippe Clevenbergh, et al.
Frontiers in Public Health (2025) Vol. 12
Open Access
Sophie Marbaix, Steven Simoens, Philippe Clevenbergh, et al.
Frontiers in Public Health (2025) Vol. 12
Open Access
Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study
Benchen Rao, Daming Wang, Mengzhao Yang, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access
Benchen Rao, Daming Wang, Mengzhao Yang, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access
Analysis of Clinical Criteria for Discharge Among Patients Hospitalized for COVID-19: Development and Validation of a Risk Prediction Model
Jeffrey L. Schnipper, Sandra Oreper, Colin C. Hubbard, et al.
Journal of General Internal Medicine (2024) Vol. 39, Iss. 14, pp. 2649-2661
Open Access | Times Cited: 2
Jeffrey L. Schnipper, Sandra Oreper, Colin C. Hubbard, et al.
Journal of General Internal Medicine (2024) Vol. 39, Iss. 14, pp. 2649-2661
Open Access | Times Cited: 2
Infectious Disease Updates for Primary Care
Denise J. McCulloch, Paul S. Pottinger
Medical Clinics of North America (2024) Vol. 108, Iss. 5, pp. 965-979
Closed Access
Denise J. McCulloch, Paul S. Pottinger
Medical Clinics of North America (2024) Vol. 108, Iss. 5, pp. 965-979
Closed Access
Viral SARS-CoV-2 Rebound Rates in Linked Commercial Pharmacy-Based Testing and Health Care Claims
Scott P. Kelly, Lisa M. McEwen, Magnus Isaksson, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 6
Open Access
Scott P. Kelly, Lisa M. McEwen, Magnus Isaksson, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 6
Open Access
Disparate SARS-CoV-2 infection outcomes abound, but what makes SARS-CoV-2 bound for rebound?
Timothy P. Sheahan
The Journal of Infectious Diseases (2024)
Open Access
Timothy P. Sheahan
The Journal of Infectious Diseases (2024)
Open Access
Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial
Kara W. Chew, Brooke McGinley, Carlee Moser, et al.
The Journal of Infectious Diseases (2024)
Closed Access
Kara W. Chew, Brooke McGinley, Carlee Moser, et al.
The Journal of Infectious Diseases (2024)
Closed Access
Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19
Mahta Mortezavi, Abigail Sloan, Ravi Shankar Prasad Singh, et al.
Clinical Infectious Diseases (2024)
Open Access
Mahta Mortezavi, Abigail Sloan, Ravi Shankar Prasad Singh, et al.
Clinical Infectious Diseases (2024)
Open Access
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2
Shadisadat Esmaeili, Katherine Owens, Joseph F. Standing, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Shadisadat Esmaeili, Katherine Owens, Joseph F. Standing, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SR
Jonathan Rawson, Eric Donaldson, Julian J. O’Rear, et al.
Clinical Infectious Diseases (2024)
Open Access
Jonathan Rawson, Eric Donaldson, Julian J. O’Rear, et al.
Clinical Infectious Diseases (2024)
Open Access
An orally available P1’-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier
Nobuyo Higashi‐Kuwata, Haydar Bulut, Hironori Hayashi, et al.
PNAS Nexus (2024) Vol. 4, Iss. 1
Open Access
Nobuyo Higashi‐Kuwata, Haydar Bulut, Hironori Hayashi, et al.
PNAS Nexus (2024) Vol. 4, Iss. 1
Open Access
